Lotta Hansson

Publications
CV
Public outreach and news

Articles

Article: EBIOMEDICINE. 2024;109:105385
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID
Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Gao Y; Soderdahl G; Osterborg A; Smith CIE; Vesterbacka J; Wullimann D; Cuapio A; Akber M; Bogdanovic G; Muschiol S; Aberg M; Lore K; Chen MS; Ljungman P; Buggert M; Aleman S; Ljunggren H-G
Article: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2024;:S0091-6749(24)01125-4
Inborn errors of immunity are associated with increased COVID-19-related hospitalization and intensive care compared to the general population.
Lindahl H; Kahn F; Nilsdotter-Augustinsson Å; Fredrikson M; Hedberg P; Killander Möller I; Hansson L; Blixt L; Eketorp Sylvan S; Österborg A; Aleman S; Carlander C; Nyström S; Bergman P
Article: INFECTIOUS DISEASES. 2024;:1-14
Risk of COVID-19 hospitalisation by HIV-status and SARS-CoV-2 vaccination status during pre- and post-Omicron era in a national register-based cohort study in Sweden
Moller IK; Hedberg P; Wagner P; Lindahl H; Nystrom S; Blixt L; Sylvan SE; Nilsdotter-Augustinsson A; Osterborg A; Fredrikson M; Hansson L; Kahn F; Sparen P; Gisslen M; Naucler P; Bergman P; Aleman S; Carlander C
Article: CELL HOST AND MICROBE. 2024;32(2):156-161.e3
Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant
Muller TR; Gao Y; Wu J; Ribeiro O; Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Soderdahl G; Smith CIE; Lore K; Chen MS; Ljungman P; Ingelman-Sundberg HM; Ljunggren H-G; Osterborg A; Sette A; Grifoni A; Aleman S; Buggert M
Article: SCIENCE IMMUNOLOGY. 2023;8(90):eadh0687
SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19
Cai C; Gao Y; Adamo S; Rivera-Ballesteros O; Hansson L; Osterborg A; Bergman P; Sandberg JK; Ljunggren H-G; Bjorkstrom NK; Stralin K; Llewellyn-Lacey S; Price DA; Qin C; Grifoni A; Weiskopf D; Wherry EJ; Sette A; Aleman S; Buggert M
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;111(5):715-721
Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients
Mattsson A; Sylvan SE; Axelsson P; Ellin F; Kjellander C; Larsson K; Lauri B; Lewerin C; Scharenberg C; Tatting L; Johansson H; Osterborg A; Hansson L
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;111(5):748-756
Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib-A retrospective analysis on consecutive patients from a well-defined region
Andersson ML; Johansson H; Osterborg A; Mansson-Broberg A; Hansson L; Palma M
Article: EBIOMEDICINE. 2023;94:104700
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID
Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Soderdahl G; oesterborg A; Smith CIE; Vesterbacka J; Wullimann D; Cuapio A; Akber M; Bogdanovic G; Muschiol S; aberg M; Lore K; Chen MS; Buggert M; Ljungman P; Aleman S; Ljunggren H-G
Article: JOURNAL OF HEMATOLOGY. 2023;12(4):170-175
Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia
Andersson M; Wu J; Wullimann D; Gao Y; Aberg M; Muschiol S; Healy K; Naud S; Bogdanovic G; Palma M; Mellstedt H; Chen P; Ljunggren H-G; Hansson L; Chen MS; Buggert M; Ingelman-Sundberg HM; Osterborg A
Article: SCIENCE TRANSLATIONAL MEDICINE. 2023;15(704):eadg9452
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states
Muller TRR; Sekine T; Trubach D; Niessl J; Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Olofsson A; Hernandez SPA; Gao Y; Cai C; Soderdahl G; Smith CIE; Osterborg A; Lore K; Sallberg Chen M; Ljungman P; Ljunggren H-G; Karlsson ACC; Saini SK; Aleman S; Buggert M
Article: HEMASPHERE. 2022;6(11):e794
Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment
Mulder TAA; Andersson MLL; Pena-Perez L; Heimersson K; Xagoraris I; Wahlin BE; Mansson R; Hansson L; Rassidakis G; Palma M
Article: IMMUNITY. 2022;55(9):1732-1746.e5
Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination
Gao Y; Cai C; Wullimann D; Niessl J; Rivera-Ballesteros O; Chen P; Lange J; Cuapio A; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Perez-Potti A; Sekine T; Muller TR; Boulouis C; Kammann T; Parrot T; Muvva JR; Sobkowiak M; Healy K; Bogdanovic G; Muschiol S; Soderdahl G; Osterborg A; Hellgren F; Grifoni A; Weiskopf D; Sette A; Lore K; Chen MS; Ljungman P; Sandberg JK; Smith CIE; Bergman P; Ljunggren H-G; Aleman S; Buggert M
Article: NATURE MEDICINE. 2022;28(3):472-476
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
Gao Y; Cai C; Grifoni A; Muller TR; Niessl J; Olofsson A; Humbert M; Hansson L; Osterborg A; Bergman P; Chen P; Olsson A; Sandberg JK; Weiskopf D; Price DA; Ljunggren H-G; Karlsson AC; Sette A; Aleman S; Buggert M
Article: MED. 2022;3(2):137-153.e3
Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals
Healy K; Pin E; Chen P; Soderdahl G; Nowak P; Mielke S; Hansson L; Bergman P; Smith CIE; Ljungman P; Valentini D; Blennow O; Osterborg A; Gabarrini G; Al-Manei K; Alkharaan H; Sobkowiak MJ; Yousef J; Mravinacova S; Cuapio A; Xu X; Akber M; Lore K; Hellstrom C; Muschiol S; Bogdanovic G; Buggert M; Ljunggren H-G; Hober S; Nilsson P; Aleman S; Chen MS
Article: MOLECULAR MEDICINE. 2022;28(1):20
NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals
Cuapio A; Boulouis C; Filipovic I; Wullimann D; Kammann T; Parrot T; Chen P; Akber M; Gao Y; Hammer Q; Strunz B; Potti AP; Ballesteros OR; Lange J; Muvva JR; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Soderdahl G; Osterborg A; Smith CIE; Bogdanovic G; Muschiol S; Hellgren F; Lore K; Sobkowiak MJ; Gabarrini G; Healy K; Chen MS; Alici E; Bjorkstrom NK; Buggert M; Ljungman P; Sandberg JK; Aleman S; Ljunggren H-G
Article: LEUKEMIA. 2022;36(2):476-481
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients
Blixt L; Bogdanovic G; Buggert M; Gao Y; Hober S; Healy K; Johansson H; Kjellander C; Mravinacova S; Muschiol S; Nilsson P; Palma M; Pin E; Smith CIE; Stromberg O; Chen MS; Zain R; Hansson L; Osterborg A
Article: EBIOMEDICINE. 2021;74:103705
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Soderdahl G; Osterborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgstrom E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin A-C; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Lore K; Chen MS; Buggert M; Ljunggren H-G; Ljungman P; Aleman S
Article: BLOOD. 2021;138(18):1768-1773
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
Roeker LE; Eyre TA; Thompson MC; Lamanna N; Coltoff AR; Davids MS; Baker PO; Leslie L; Rogers KA; Allan JN; Cordoba R; Lopez-Garcia A; Antic D; Pagel JM; Martinez-Calle N; Antonio Garcia-Marco J; Hernandez-Rivas J-A; Miras F; Coombs CC; Osterborg A; Hansson L; Seddon AN; Lopez Jimenez J; Wilson MR; El-Sharkawi D; Wojenski D; Ma S; Munir T; Valenciano S; Seymour E; Barr PM; Pu J; Patten PEM; Perini GF; Huntington SF; Parry H; Sundaram S; Skarbnik A; Kamdar M; Jacobs R; Walter H; Walewska R; Broom A; Lebowitz S; Isaac KM; Portell CA; Ahn IE; Ujjani CS; Shadman M; Skanland S; Chong EA; Mato AR
Article: EJHAEM. 2021;2(3):525-529
Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia
Lundin J; Mulder TA; Kattstrom M; Wasterlid T; Uddevik A; Mellstedt H; Heimersson K; Hansson L; Palma M; Osterborg A
Article: EJHAEM. 2021;2(3):400-412
Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years
Wahlin BE; Overgaard N; Peterson S; Digkas E; Glimelius I; Lagerlof I; Johansson A-S; Palma M; Hansson L; Linderoth J; Goldkuhl C; Molin D
Article: HAEMATOLOGICA. 2021;106(1):87-97
Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multicenter study
Leeksma AC; Baliakas P; Moysiadis T; Puiggros A; Plevova K; van der Kevie-Kersemaekers A-M; Posthuma H; Rodriguez-Vicente AE; Tran AN; Barbany G; Mansouri L; Gunnarsson R; Parker H; van den Berg E; Bellido M; Davis Z; Wall M; Scarpelli I; Osterborg A; Hansson L; Jarosova M; Ghia P; Poddighe P; Espinet B; Pospisilova S; Tam C; Ysebaert L; Nguyen-Khac F; Oscier D; Haferlach C; Schoumans J; Stevens-Kroef M; Eldering E; Stamatopoulos K; Rosenquist R; Strefford JC; Mellink C; Kater AP
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;191(3):426-432
Risk-adapted bendamustine plus rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients
Mattsson A; Sylvan SE; Asklid A; Wiggh J; Winqvist M; Lundin J; Mansouri L; Rosenquist R; Johansson H; Osterborg A; Hansson L
Article: BLOOD. 2020;136(10):1134-1143
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Mato AR; Roeker LE; Lamanna N; Allan JN; Leslie L; Pagel JM; Patel K; Osterborg A; Wojenski D; Kamdar M; Huntington SF; Davids MS; Brown JR; Antic D; Jacobs R; Ahn IE; Pu J; Isaac KM; Barr PM; Ujjani CS; Geyer MB; Berman E; Zelenetz AD; Malakhov N; Furman RR; Koropsak M; Bailey N; Hanson L; Perini GF; Ma S; Ryan CE; Wiestner A; Portell CA; Shadman M; Chong EA; Brander DM; Sundaram S; Seddon AN; Seymour E; Patel M; Martinez-Calle N; Munir T; Walewska R; Broom A; Walter H; El-Sharkawi D; Parry H; Wilson MR; Patten PEM; Hernandez-Rivas J-A; Miras F; Escalada NF; Ghione P; Nabhan C; Lebowitz S; Bhavsar E; Lopez-Jimenez J; Naya D; Garcia-Marco JA; Skanland SS; Cordoba R; Eyre TA
Article: LEUKEMIA AND LYMPHOMA. 2020;61(9):2136-2144
A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy
Asklid A; Sylvan SE; Mattsson A; Winqvist M; Johansson H; Osterborg A; Hansson L
Article: HAEMATOLOGICA. 2019;104(4):797-804
FFirst-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
Sylvan SE; Asklid A; Johansson H; Klintman J; Bjellvi J; Tolvgard S; Kimby E; Norin S; Andersson P-O; Karlsson C; Karlsson K; Lauri B; Mattsson M; Sandstedt AB; Strandberg M; Osterborg A; Hansson L
Article: LEUKEMIA. 2018;32(10):2291-2295
First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells
Hojjat-Farsangi M; Daneshmanesh AH; Khan AS; Shetye J; Mozaffari F; Kharaziha P; Rathje L-S; Kokhaei P; Hansson L; Vagberg J; Bystrom S; Olsson E; Lofberg C; Norstrom C; Schultz J; Norin M; Olin T; Osterborg A; Mellstedt H; Moshfegh A
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2018;101(1):68-77
Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients
Palma M; Hansson L; Mulder TA; Adamson L; Nasman-Glaser B; Eriksson I; Heimersson K; Ryblom H; Mozaffari F; Svensson A; Gentilcore G; Osterborg A; Mellstedt H
Article: CLINICAL CANCER RESEARCH. 2018;24(8):1834-1844
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
Bjorklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikstrom K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellstrom-Lindberg E; Ljunggren H-G; Malmberg K-J
Article: PLOS ONE. 2018;13(6):e0198038
A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib
Daneshmanesh AH; Hojjat-Farsangi M; Ghaderi A; Moshfegh A; Hansson L; Schultz J; Vagberga J; Bystrom S; Olsson E; Olin T; Osterborg A; Mellstedt H
Article: PLOS ONE. 2018;13(2):e0192839
Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells
Kokhaei P; Hojjat-Farsangi M; Mozaffari F; Moshfegh A; Pak F; Rashidy-Pour A; Palma M; Hansson L; Osterborg A; Mellstedt H
Article: ANNALS OF HEMATOLOGY. 2017;96(10):1681-1691
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
Hansson L; Asklid A; Diels J; Eketorp-Sylvan S; Repits J; Soltoft F; Jaeger U; Osterborg A
Article: HAEMATOLOGICA. 2017;102(3):562-572
T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
Palma M; Gentilcore G; Heimersson K; Mozaffari F; Nasman-Glaser B; Young E; Rosenquist R; Hansson L; Osterborg A; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2017;66(1):91-102
Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
Winqvist M; Mozaffari F; Palma M; Sylvan SE; Hansson L; Mellstedt H; Osterborg A; Lundin J
Article: HAEMATOLOGICA. 2016;101(12):1573-1580
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Osterborg A
Article: TUMOR BIOLOGY. 2016;37(9):11947-11957
Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia
Khan AS; Hojjat-Farsangi M; Daneshmanesh AH; Hansson L; Kokhaei P; Osterborg A; Mellstedt H; Moshfegh A
Article: LEUKEMIA RESEARCH. 2015;39(1):33-37
Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: Results from a Swedish national observational study
Norin S; Bjorkstrand B; Rommel F; Timberg L; Andersson P-O; Haggstrom J; Aldrin A; Hansson L
Article: PLOS ONE. 2015;10(11):e0142310
Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.
Hojjat-Farsangi M; Jeddi-Tehrani M; Daneshmanesh AH; Mozaffari F; Moshfegh A; Hansson L; Razavi SM; Sharifian RA; Rabbani H; Österborg A; Mellstedt H; Shokri F
Article: ANNALS OF HEMATOLOGY. 2014;93(10):1725-1733
Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients
Sylvan SE; Lundin J; Ipek M; Palma M; Karlsson C; Hansson L
Article: LEUKEMIA AND LYMPHOMA. 2014;55(8):1774-1780
Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region
Sylvan SE; Hansson L; Karlsson C; Norin S; Lundin J; Osterborg A
Article: EXPERIMENTAL HEMATOLOGY. 2013;41(7):615-626
Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia
Palma M; Parker A; Hojjat-Farsangi M; Forster J; Kokhaei P; Hansson L; Osterborg A; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2013;62(1):51-63
T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile
Kiaii S; Kokhaei P; Mozaffari F; Rossmann E; Pak F; Moshfegh A; Palma M; Hansson L; Mashayekhi K; Hojjat-Farsangi M; Osterborg A; Choudhury A; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2012;61(6):865-879
Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria
Palma M; Hansson L; Choudhury A; Nasman-Glaser B; Eriksson I; Adamson L; Rossmann E; Widen K; Horvath R; Kokhaei P; Vertuani S; Mellstedt H; Osterborg A
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2009;69(6):529-536
Generation of a Dendritic Cell-based Vaccine in Chronic Lymphocytic Leukaemia Using CliniMACS Platform for Large-scale Production
Adamson L; Palma M; Choudhury A; Eriksson I; Nasman-Glaser B; Hansson M; Hansson L; Kokhaei P; Osterborg A; Mellstedt H
Article: ANNALS OF ONCOLOGY. 2008;19(6):1172-1179
Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC)
Abdalla AO; Kokhaei P; Hansson L; Mellstedt H; Osterborg A
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2007;79(5):371-381
Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients
Abdalla AO; Hansson L; Eriksson I; Nasman-Glaser B; Mellstedt H; Osterborg A
Article: CLINICAL CANCER RESEARCH. 2007;13(12):3536-3544
Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies
Kokhaei P; Abdalla AO; Hansson L; Mikaelsson E; Kubbies M; Haselbeck A; Jernberg-Wiklund H; Mellstedt H; Osterborg A
Article: CLINICAL CANCER RESEARCH. 2007;13(5):1503-1510
Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients
Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
Article: LEUKEMIA. 2007;21(3):511-514
Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody)
Karlsson C; Hansson L; Celsing F; Lundin J
Article: EXPERIMENTAL HEMATOLOGY. 2007;35(2):297-304
Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells
Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
Article: HAEMATOLOGICA. 2007;92(1):110-114
Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma -: evaluation of T-cell responses by different read-out systems
Abdalla AO; Hansson L; Eriksson I; Nasman-Glaser B; Rossmann ED; Rabbani H; Mellstedt H; Osterborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2004;124(3):315-324
Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage
Mozaffari F; Hansson L; Kiaii S; Ju XL; Rossmann ED; Rabbani H; Mellstedt H; Österborg A
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2003;58(6):601-606
Kinetics of cytokine gene expression in human CD4⁺ and CD8⁺ T-lymphocyte subsets using quantitative real-time PCR
Abdalla AO; Kiaii S; Hansson L; Rossmann ED; Jeddi-Tehrani M; Shokri F; Österborg A; Mellstedt H; Rabbani H
Article: BLOOD. 2003;101(12):4930-4936
T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma
Hansson L; Rabbani H; Fagerberg J; Österborg A; Mellstedt K
Article: BLOOD. 2003;101(11):4607-4610
Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells
Rasmussen T; Hansson L; Österborg A; Johnsen HE; Mellstedt H
Article: BLOOD. 1998;91(7):2459-2466
Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses
Österborg A; Yi Q; Henriksson L; Fagerberg J; Bergenbrant S; Jeddi-Tehrani M; Rudén U; Lefvert AK; Holm G; Mellstedt H
Show more

All other publications

Letter: HAEMATOLOGICA. 2024;109(2):646-651
Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia
Ingelman-Sundberg HM; Blixt L; Wullimann D; Wu J; Gao Y; Healy K; Muschiol S; Bogdanovic G; Aberg M; Kjellander C; Grifoni A; Sette A; Aleman S; Chen P; Blennow O; Hansson L; Ljunggren H-G; Chen MS; Buggert M; Osterborg A
Letter: ACTA ONCOLOGICA. 2023;62(6):560-564
The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results
Smedby KE; Waesterlid T; Tham E; Haider Z; Joelsson J; Thorvaldsdottir B; Krstic A; Wahlin BE; Foroughi-Asl H; Karlsson C; Eloranta S; Saft L; Palma M; Kwiecinska A; Hansson L; Osterborg A; Wirta V; Rassidakis G; Sander B; Sonnevi K; Rosenquist R
Letter: BLOOD. 2022;140(22):2403-2407
Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination
Blixt L; Gao Y; Wullimann D; Ingelman-Sundberg HM; Muschiol S; Healy K; Bogdanovic G; Pin E; Nilsson P; Kjellander C; Grifoni A; Sette A; Chen MS; Ljunggren H-G; Buggert M; Hansson L; Osterborg A
Letter: HAEMATOLOGICA. 2022;107(4):1000-1003
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial
Blixt L; Wullimann D; Aleman S; Lundin J; Chen P; Gao Y; Cuapio A; Akber M; Lange J; Rivera-Ballesteros O; Buggert M; Ljunggren H-G; Hansson L; Osterborg A
Letter: HAEMATOLOGICA. 2019;104(5):E208-E210
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort
Winqvist M; Andersson P-O; Asklid A; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Rosenquist R; Spath F; Hansson L; Osterborg A
Letter: LEUKEMIA AND LYMPHOMA. 2017;58(5):1219-1223
Outcomes of second-line treatment in chronic lymphocytic leukemia - a population-based study from a well defined geographical region between 2003 and 2013
Asklid A; Winqvist M; Sylvan SE; Mattsson A; Bjorgvinsson E; Soltoft F; Repits J; Diels J; Osterborg A; Hansson L
Meeting abstract: BLOOD. 2015;126(23):1745
Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program
Hansson L; Winqvist M; Asklid A; Andersson P-O; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Osterborg A
Meeting abstract: LEUKEMIA RESEARCH. 2015;39:S25-S26
ADOPTIVELY TRANSFERRED HAPLOIDENTICAL NK CELLS AGAINST REFRACTORY MDS, HIGH-RISK MDS AND REFRACTORY AML AS A BRIDGE TO TRANSPLANTATION. COMPLETE REMISSION ASSOCIATED WITH DETECTABLE NK CELLS
Bjorklund AT; Carlsten M; Liu L; Schaffer M; Watz E; Palma M; Hansson L; Mollgard L; Cooley SA; Miller JS; Ljungman PT; Hellstrom-Lindberg E; Ljunggren HG; Malmberg KJ
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2012;159(5):608-612
Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression
Sylvan SE; Rossmann E; Mozaffari F; Porwit A; Norin S; Karlsson C; Hansson L; Lundin J; Osterborg A
Letter: BLOOD CANCER JOURNAL. 2011;1(6):e22
Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia
Karlsson C; Dahl H; Lundin J; Rossmann E; Brytting M; Mellstedt H; Linde A; Osterborg A
Published conference paper: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2008;57(11):1705-1710
Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia
Palma M; Adamson L; Hansson L; Kokhaei P; Rezvany R; Mellstedt H; Oesterborg A; Choudhury A
Review: ADVANCES IN CANCER RESEARCH. 2006;95:147-202
Clinical results of vaccine therapy for cancer: Learning from history for improving the future
Choudhury A; Mosolits S; Kokhaei P; Hansson L; Palma M; Mellstedt H
Meeting abstract: BLOOD. 2004;104(11):419A
Long-term Id vaccination combined with IL-12 or IL-12 and GM-CSF in early stage multiple myeloma patients
Hansson L; Abdalla AO; Rabbani H; Osterborg A; Mellstedt H
Thesis / dissertation: 2004
Natural and induced idiotype immunity in patients with multiple myeloma
Hansson, Lotta
Published conference paper: ACTA ONCOLOGICA. 2000;39(7):797-800
Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma
Österborg A; Henriksson L; Mellstedt H
Review: CURRENT OPINION IN HEMATOLOGY. 1999;6(3):169-175
Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors.
Mellstedt H; Fagerberg J; Frödin JE; Henriksson L; Hjelm-Skoog AL; Liljefors M; Ragnhammar P; Shetye J; Osterborg A

Employments

Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2022-2025

Degrees and Education

Docent, Karolinska Institutet, 2015
Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2004
University Medical Degree, Karolinska Institutet, 1993

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI